Kailera Therapeutics

Obesity/metabolic small-molecule & peptide GLP-1 portfolio (licensed from Hengrui)

KLRA · Nasdaq · United States

Share price · KLRA

$11.79-6.04 (-33.88%) 3M

close as of 2026-11-18 · 24h delayed · vol 419K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KLRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 20 Oct 2026+12.8%
  2. 9 Oct 2026+16.1%
  3. 24 Sep 2026-8.8%
  4. 21 Sep 2026-6.5%
  5. 9 Sep 2026-9.7%
  6. 28 Aug 2026-12.5%
  7. 22 Jun 2026+15.0%

    Nothing announced by KLRA that day or the session before.

Share of unusual movement by asset

For each asset, the share of KLRA's own-move activity since 20 Apr 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
ribupatide
events and moves
2shown from 8 days
Safiglipron (HRS-7535)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—8%
Sessions with no dated event—90%

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 DiabetesHeart FailureAtherosclerotic Cardiovascular Disease
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 DiabetesHypertensionHeart FailureChronic Kidney Disease
Phase 2
GLP-1/GIP/glucagon receptor (triple)Peptide
Obesity

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Safiglipron (HRS-7535)Phase 2Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Est. primary completion 2026-12 · NCT06820099 · CT.gov ↗
What to watch
2027 (3)
May 2027 (1)
ribupatidePhase 2Obesity
Est. primary completion 2027-05 · NCT07458269 · CT.gov ↗
What to watch
July 2027 (1)
Safiglipron (HRS-7535)Phase 2Obesity, Overweight
Est. primary completion 2027-07-07 · NCT07497880 · CT.gov ↗
What to watch
December 2027 (1)
Safiglipron (HRS-7535)Phase 3Hypertension With Overweight or Obesity
Est. primary completion 2027-12 · NCT07528027 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
ribupatidePhase 3Obesity, Overweight
Est. primary completion 2028-02 · NCT07284875 · CT.gov ↗
What to watch
March 2028 (2)
ribupatidePhase 3Obesity
Est. primary completion 2028-03 · NCT07284979 · CT.gov ↗
What to watch
ribupatidePhase 3Obesity With Diabetes, Overweight With Diabetes
Est. primary completion 2028-03-27 · NCT07284901 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Safiglipron (HRS-7535)Phase 3Chronic Kidney Disease
Est. primary completion 2031-05 · NCT07625774 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 September 2026Filing acceptedSafiglipron (HRS-7535)NMPA accepts Hengrui's marketing application for HRS-7535 tablets in type 2 diabetes
CN, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗
2 September 2025Filing acceptedribupatideNMPA accepts the HRS9531 (ribupatide) marketing application for weight management (reported 2025-09-02)
CN, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$85M$107M+ $795M short-term inv.$96M-$134M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$101M$130M+ $786M short-term inv.$111M-$78M operating cash flowreport ↗
2026-Q1—$71M$112M+ $407M short-term inv.$79M-$68M operating cash flowreport ↗
2025-Q3—$27M$98M$40M-$30M operating cash flowreport ↗
2025-Q2—$20M$101M$29M-$26M operating cash flowreport ↗
2025-Q1—$10M$102M$18M-$18M operating cash flowreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$160M+ $386M short-term inv.—report ↗

Kailera Therapeutics reported cash and equivalents of $160.27M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($326.8M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-07Nicholson Nur · Chief Technology OfficerAward / grant (derivative)220,000——Form 4
2026-07-06Tregoning Kathleen · See RemarksAward / grant (derivative)175,000——Form 4
2026-06-09Renaud Ronald C JR · director, CEO & PresidentOption exercise38,094$5.25$200KForm 4
2026-06-09Renaud Ronald C JR · director, CEO & PresidentOption exercise (derivative)38,094——Form 4
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd. · 10% ownerConversion9,477,719——Form 4
2026-04-20RTW INVESTMENTS, LP; WONG RODERICK · 10% owner; 10% ownerConversion10,276,820——Form 4
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd. · 10% ownerConversion2,034,133——Form 4
2026-04-20RTW INVESTMENTS, LP; WONG RODERICK · 10% owner; 10% ownerOpen-market purchase500,000$16.00$8.0MForm 4